AMLX vs PRU · $561.6M cap vs rev $31.19B
Amylyx Pharmaceuticals Inc (AMLX) versus PRU (PRU) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
PRU (PRU) common stock.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
Latest reported PRU revenue for 2026-06-30 was $31.19B. Net income was $1.58B. PRU currently screens at market cap $0.
AMLX currently screens at market cap $561.6M. PRU currently screens at market cap $0.
Not investment advice. Open the AMLX and PRU stock pages for the full models.
Not investment advice.